Rockwell Medical (RMTI) Research & Development (2010 - 2026)

Rockwell Medical (RMTI) has reported Research & Development for 17 consecutive years, with $577000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 0.87% year-over-year to $577000.0; the trailing twelve-month figure through Jun 2026 stood at $2.2 million (down 22.34% YoY), and the FY2025 full-year result was $2.4 million, down 14.37% from the prior year.
• Research & Development advanced to $577000.0 in Q2 2026 per RMTI's latest filing, from $567000.0 in the prior quarter.
• Across five years, Research & Development topped out at $1.6 million in Q1 2022 and bottomed at $156000.0 in Q4 2022.
• Historically, Research & Development has averaged $654611.1 across 5 years, with a median of $574500.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Research & Development tumbled 88.78% in 2022, then surged 246.79% in 2023.
• Over 5 years, Research & Development stood at $156000.0 in 2022, then soared by 246.79% to $541000.0 in 2023, then surged by 55.82% to $843000.0 in 2024, then slumped by 35.94% to $540000.0 in 2025, then advanced by 6.85% to $577000.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $577000.0, $567000.0, and $540000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.